- Injective price remains above critical support near the $4.10 level
- ETF speculation and institutional partnerships boosted bullish sentiment
- Injective recorded strong developer activity and completed another buyback
Injective price remained volatile over the past 24 hours after a strong rally earlier this week. INJ traded near $4.15 at press time, down 2.52% on the day after recently reaching the $4.40 target highlighted by analyst ChiefraT.
ChiefraT noted that INJ delivered a quick 15.5% move before facing short-term resistance. Analysts now believe the Injective price could continue higher toward the $5.50 region if key support levels remain intact.
Injective Price Holds Key Support Above $4.10
The current Injective price structure remains constructive while buyers defend the important pivot zone near $4.10. Market analysts believe maintaining this level could allow INJ to consolidate before attempting another rebound toward $4.26 and higher resistance areas.
However, losing the $4.10 support may increase downside pressure. In that case, traders expect the Injective price to revisit the 200-day moving average near $3.89. Short-term sentiment remains tied to whether bulls can preserve higher lows after the recent breakout attempt.
Injective Price Gains Support From Institutional Developments
Several major developments have boosted confidence in the Injective ecosystem this week. IKAY highlighted that USDC and Circle’s Cross-Chain Transfer Protocol recently launched on the network, expanding liquidity access and cross-chain functionality.
Institutional interest has also increased following discussions at Consensus 2026 regarding regulated futures products tied to Injective. Market participants now speculate that an INJ-focused ETF could emerge sooner than expected due to existing regulated futures infrastructure.
Another major catalyst came from an SEC S-4 filing confirming Injective as a native blockchain partner for Securitize. The platform works with major firms including BlackRock, Apollo, and KKR, strengthening Injective’s role in tokenized finance infrastructure.
The network also completed another token buyback this week, with scheduled token burns expected within days. Meanwhile, Injective ranked among the top blockchain networks for monthly revenue generation and recorded the highest code commits over the past 24 hours, surpassing Ethereum and Sui.
Disclaimer:Â This article is for informational purposes only and does not constitute financial advice. CoinCryptoNewz is not responsible for any losses incurred. Readers should do their own research before making financial decisions.
